Bayer Healthcare Aktiengesellschaft

Boehringer Ingelheim International Gmbh

Bayer Schering Pharma Ag

Other

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Frank-Gerhard Böss

Martin Hendrix

Christina Erb

Joachim Luithle

Marja Van Kampen

Christoph Methfessel

Timo Flessner

Frank-Thorsten Hafner

Rudy Schreiber

Karl-Heinz Schlemmer

Frank Wunder

Franz-Josef Van Der Staay

Leila Telan

Katrin Schnizler

Dagmar Schauss

Gerhard König

Dieter Lang

Toshiya Moriwaki

Joachim Krüger

Welf-Burkhard Wiese

Ulrich Niewöhner

Maria Niewöhner, Legal Representative

The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory.

Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes

The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them.

N-biarylamides

The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.

Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

Heteroaryl carboxylic acid amides

This application relates to bicyclic N-aryl amides of the formula Ris a-aza-bicyclo[]octyl group, a-aza-bicyclo[]oct--yl; Ris an optionally sustituted- to- membered heteroaryl, naphthyl, or azulenyl group; and Ris H or (CC)alkyl; or a salt, solvate, or solvate of a salt of these compounds. A process for preparing these compounds, medicaments containing them, and methods for using them in treatment are also disclosed and claimed.

Bicyclic N-arylamides

The invention relates to novel 1-aza-bicyclic N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.

Aza-bicyclic N-biarylamides with affinity for the &#x3b1;7 nicotinic acetylcholine receptor

The invention relates to the use of selective phosphodiesterase 2 (PDE 2) inhibitors for producing pharmaceuticals for improving perception, concentration, learning and/or memory.

Selective PDE 2 inhibitors as pharmaceuticals for improving perception

The invention relates to novel substituted imidazotriazinones, to a method for their production and to the use thereof for producing medicaments, in particular to improve perception, powers of concentration, learning capacity and/or memory retentiveness.

Substituted imidazotriazinones

Growing community of inventors

Berkshire, United Kingdom

Frank-Gerhard Böss